Evidence map›Paper›PMID 36306479›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.

Gilberto de Castro, Iveta Kudaba, Yi-Long Wu, Gilberto Lopes, Dariusz M Kowalski, Hande Z Turna, Christian Caglevic, Li Zhang, Boguslawa Karaszewska, Konstantin K Laktionov and 8 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 221 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
221citing papers in PubMed, 13 pooled it
27.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

221 citing papers in PubMed, 13 syntheses or guidelines pooled it, 288 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. PD-L1 imaging with [British journal of cancer · 2025
    Trial
  19. Trial
  20. Trial

161 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 14 countries.

Gilberto de CastroInstituto do Câncer do Estado de São Paulo, São Paulo, Brazil.ORCID 0000-0001-8765-3044
Iveta KudabaLatvian Oncology Center, Riga East Clinical University, Riga, Latvia.
Yi-Long WuGuangdong Lung Cancer Institute, Guangdong Provinicial People's Hospital and Guangdong Academy of Medical Sciences, Guandong, China.ORCID 0000-0002-3611-0258
Gilberto LopesDepartment of Medical Oncology, Sylvester Comprehensive Cancer Center at the University of Miami, FL.ORCID 0000-0002-1151-9903
Dariusz M KowalskiDepartment of Lung Cancer and Chest Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.ORCID 0000-0002-9452-3229
Hande Z TurnaDepartment of Internal Medicine, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey.
Christian CaglevicCancer Research Department, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile.ORCID 0000-0003-3319-1678
Li ZhangPeking Union Medical College Hospital, Beijing, China.
Boguslawa KaraszewskaPrzychodnia Lekarska KOMED, Konin, Poland.
Konstantin K LaktionovFederal State Budgetary Institution, "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russia.
Vichien SrimuninnimitDepartment of Medicine, Siriraj Hospital, Bangkok, Thailand.
Igor BondarenkoOncology and Medical Radiology Department, Dnipro State Medical Academy, Dnipro, Ukraine.ORCID 0000-0002-7071-2471
Kaoru KubotaDepartment of Pulmonary Medicine and Oncology, Nippon Medical School Hospital, Tokyo, Japan.
Rinee MukherjeeMerck & Co, Inc, Rahway, NJ.
Jianxin LinMerck & Co, Inc, Rahway, NJ.
Fabricio SouzaMerck & Co, Inc, Rahway, NJ.
Tony S K MokClinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Shatin, Hong Kong, China.ORCID 0000-0002-8251-0551
Byoung Chul ChoDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-5562-270X
Merck & Co., Inc., Rahway, NJ, USA (United States) · USChinese Academy of Medical Sciences & Peking Union Medical College · CNChinese University of Hong Kong · HKDnipro State Medical University · UAFundación Arturo López Pérez · CLGuangdong Academy of Medical Sciences · CNInstituto do Câncer do Estado de São Paulo · BRIstanbul University-Cerrahpaşa · TRMinistry of Health · ESNippon Medical School Hospital · JPRiga East University Hospital · LVSiriraj Hospital · THThe Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversity of Miami · USYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCarboplatinErbB ReceptorsHumansPaclitaxelPemetrexedReceptor Protein-Tyrosine KinasesAntibodies, Monoclonal, HumanizedB7-H1 AntigenCarboplatinCD274 protein, humanErbB ReceptorsPaclitaxelpembrolizumabPemetrexedReceptor Protein-Tyrosine Kinases

Identifiers

PMID36306479
PMCPMC10082298
OpenAlexW4307585126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.